Attention-deficit hyperactivity disorder (ADHD) is a developmental disorder characterized by inattentiveness, hyperactivity, and impulsivity, often treated with amphetamine and methylphenidate agents. There is limited published data to provide established guidelines for stimulant use during pregnancy, and even less data on particular medications. This case study reports maternal–fetal outcomes with lisdexamfetamine (Vyvanse) use during pregnancy and breastfeeding. The patient who received this medication during her second pregnancy experienced significant improvement in her mental well-being compared to her first pregnancy, despite a similar pregnancy course and fetal outcomes, including preterm delivery, neonatal intensive care unit admission, cleft palate, and micrognathia in both pregnancies. In addition, this case demonstrates one instance of successful breastfeeding with maternal use of lisdexamfetamine with no observed side effects in the infant. This report highlights the importance of managing ADHD during pregnancy and the postpartum period and offers an example of breastfeeding without significant side effects or concerns.
Tran et al. (Wed,) studied this question.